

CITATION REPORT

List of articles citing

The natural history of non-alcoholic fatty liver disease

DOI: 10.1159/000282081

Digestive Diseases, 2010, 28, 162-8.

Source: <https://exaly.com/paper-pdf/49170552/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
139	Nonalcoholic Fatty Liver Disease. 2011 , 868-907		1
138	Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. <i>Obesity Surgery</i> , 2011 , 21, 1714-20	3.7	35
137	Synergistic effect of alcohol consumption and body mass on serum concentrations of cytokeratin-18. 2011 , 35, 2202-8		7
136	Dangfei liganning capsules attenuate the susceptibility of rat nonalcoholic fatty liver to carbon tetrachloride toxicity. 2011 , 31, 327-33		9
135	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. 2011 , 56, 3439-49		69
134	Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. 2011 , 54, 463-71		372
133	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. 2011 , 54, 837-45		63
132	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. 2011 , 5, 279-89		48
131	The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. 2011 , 4, 249-63		56
130	Effects of <i>Lactobacillus rhamnosus</i> strain GG in pediatric obesity-related liver disease. 2011 , 52, 740-3		217
129	Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). 2012 , 35, 873-8		172
128	Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding. 2012 , 36, 336-41		13
127	Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. 2012 , 86, 107-13		43
126	Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. 2012 , 5, 587-96		10
125	The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 262-9	2.2	25
124	Roles of PPARs in NAFLD: potential therapeutic targets. 2012 , 1821, 809-18		190
123	Regulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effect. 2012 , 1818, 1536-44		34

122	Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. 2012 , 39, 1026-33		25
121	Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. 2012 , 142, 711-725.e6		555
120	Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. 2012 , 18, 357-9		25
119	Recent trend of clinical features in patients with hepatocellular carcinoma. 2012 , 42, 368-75		68
118	Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. 2013 , 71, 753-71		27
117	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. 2013 , 28, 40-51		46
116	Manage non-alcoholic fatty liver disease using lifestyle interventions, as evidence for the use of pharmacological options is limited. 2013 , 29, 228-231		
115	Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list. 2013 , 26, 435-42		20
114	Herbal medicines for fatty liver diseases. 2013 , CD009059		29
113	Nonalcoholic fatty liver disease: current issues and novel treatment approaches. 2013 , 73, 1-14		123
112	Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease. 2013 ,		1
111	Material density hepatic steatosis quantification on intravenous contrast-enhanced rapid kilovolt (peak)-switching single-source dual-energy computed tomography. 2013 , 37, 904-10		24
110	Therapy of experimental NASH and fibrosis with galectin inhibitors. <i>PLoS ONE</i> , 2013 , 8, e83481	3.7	127
109	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013 , 19, 57-64	5.6	77
108	Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12182-201	5.6	40
107	Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease. 2014 , 2014, 1-7		2
106	Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014 , 6, 199-206	3.4	50
105	Nonalcoholic fatty liver disease and bariatric surgery in adolescents. 2014 , 23, 49-57		18

104	Interactions between the intestinal microbiome and liver diseases. 2014 , 146, 1513-24		596
103	PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. 2014 , 276, 73-81		40
102	Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. 2015 , 15, 169		47
101	ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. 2015 , 5, 16494		44
100	Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report. 2015 , 9, 36-43		4
99	Obesity as a cause of hepatocellular carcinoma. 2015 , 14, 299-303		15
98	Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015 , 7, 1679-84	3.4	19
97	Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 1189-96	5.6	82
96	Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. 2015 , 41, 65-76		140
95	The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. 2015 , 64, 380-90		79
94	CIDE/C/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis. 2015 , 61, 1227-38		53
93	Lipid Management. 2015 ,		1
92	Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. 2015 , 115, 1402-6		20
91	Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients. 2015 , 42, 357-63		5
90	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. 2015 , 149-173		1
89	Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. 2015 , 56, 722-736		193
88	[S2k Guideline non-alcoholic fatty liver disease]. 2015 , 53, 668-723		85
87	The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. 2015 , 9, 406-15		28

86	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. 2015 , 35, 221-35		235
85	Caring for children with NAFLD and navigating their care into adulthood. 2015 , 12, 617-28		16
84	Dealing with abnormal test results in diabetes. 2016 , 2016, 22-26		2
83	Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. 2016 , 2016, 6420408		3
82	Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. 2016 , 32, 1396-1401		15
81	Hepatokines and non-alcoholic fatty liver disease. 2016 , 63,		5
80	Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. 2016 , 17,		38
79	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2016 , 165, 305-15	8	494
78	The enteric microbiome in hepatobiliary health and disease. <i>Liver International</i> , 2016 , 36, 480-7	7.9	22
77	Obesity, NASH, and HCC. 2016 , 275-286		
76	Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease. 2016 , 21-40		1
75	Epidemiology and natural history of non-alcoholic fatty liver disease. 2016 , 65, 1017-25		233
74	Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. 2016 , 278, 782-91		38
73	Gut Microbiota and Complications of Liver Disease. 2017 , 46, 155-169		54
72	Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. 2017 , 131, 1905-1917		27
71	Helicobacter pylori infection and extragastric diseases in 2017. 2017 , 22 Suppl 1, e12411		30
70	Nonalcoholic Fatty Liver Disease. 2017 , 867-908		1
69	The Possible Role of Infection in Non-alcoholic Fatty Liver Disease. 2017 , 8, 743		35

68	The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. 2017 , 13, 1493-1498		13
67	Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women. <i>PLoS ONE</i> , 2017 , 12, e0182708	3.7	2
66	Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. 2017 , 14, 49		45
65	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. 2018 , 2, 43-51		44
64	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. 2018 , 41, 328-349		30
63	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. 2018 , 67, 328-357		2641
62	Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver. 2018 , 314, E165-E173		27
61	Treatment of NASH with Gastric Bypass. 2018 , 20, 49		10
60	Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. <i>PLoS ONE</i> , 2018 , 13, e0203054	3.7	36
59	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. 2018 , 41, 328-349		1
58	Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. 2018 , 8, 390-402		17
57	Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. 2018 , 2018, 2784537		46
56	New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. 2018 , 19,		72
55	Epigallocatechin-3-gallate protects against 1,3-dichloro-2-propanol-induced lipid accumulation in C57BL/6J mice. <i>Life Sciences</i> , 2018 , 209, 324-331	6.8	7
54	Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. <i>World Journal of Gastroenterology</i> , 2018 , 24, 461-474	5.6	4
53	Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome. 2018 , 2018, 8490242		13
52	Gastrointestinal Complications of Diabetes. <i>Clinical Gastroenterology</i> , 2018 ,	0	
51	Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis. 2019 , 58, 1759-1769		27

50	Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. 2019 , 18, 796-803		22
49	Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. 2019 , 15, 502-511		81
48	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. 2019 , 16, 133-143		63
47	ESPEN guideline on clinical nutrition in liver disease. 2019 , 38, 485-521		202
46	High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. 2019 , 66, 637-645		6
45	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. 2019 , 245-274		
44	Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. 2019 , 99, 1335-1348		11
43	Cherry Anthocyanins Regulate NAFLD by Promoting Autophagy Pathway. 2019 , 2019, 4825949		29
42	Anti-fibrotic activity of and paramylon in a mouse model of non-alcoholic steatohepatitis. 2019 , 7, 139-147		15
41	Nonalcoholic Fatty Liver Disease. 2019 , 523-546		
40	Comparative analysis of indices of the metabolic syndrome in patients with and without non-alcoholic fatty liver disease at a teaching hospital in Nnewi, South-East, Nigeria. 2019 , 10, 40-45		1
39	Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. <i>Medicine (United States)</i> , 2019 , 98, e17781	1.8	15
38	Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 124, 144-153	3.1	16
37	Consumption of decaffeinated coffee protects against the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function. <i>Redox Biology</i> , 2019 , 21, 101092	11.3	15
36	A nomogram for estimating the probability of nonalcoholic fatty liver disease in a Chinese population: A retrospective cohort study. <i>Medicine (United States)</i> , 2020 , 99, e23049	1.8	1
35	Increased prevalence of portal vein thrombosis in patients with nonalcoholic steatohepatitis-cirrhosis due to increased proinflammatory cytokines releasing from abdominal adipose tissue. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 458	2.2	0
34	Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2021 , 58, 319-327	3.9	3
33	Study on the correlation between urinary retinol-binding protein and nonalcoholic fatty liver disease. <i>Journal of Medical Biochemistry</i> , 2021 , 40, 86-91	1.9	

32	Leukocyte cell-derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT-1 pathway in mice. <i>Liver International</i> , 2021 , 41, 777-787	7.9	2
31	Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2021 , 31, 2762-2772	3.7	10
30	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. <i>Life Sciences</i> , 2021 , 271, 119220	6.8	11
29	Obesity-Related Comorbidities. 2015 , 25-34		2
28	Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <i>Nuclear Receptor Research</i> , 2017 , 4,	1.4	10
27	Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e95604	3.7	27
26	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. <i>Advanced Pharmaceutical Bulletin</i> , 2020 , 10, 542-555	4.5	3
25	Betaine and nonalcoholic steatohepatitis: back to the future?. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3663-4	5.6	9
24	Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. <i>World Journal of Gastroenterology</i> , 2015 , 21, 9607-13	5.6	28
23	Association between non-alcoholic fatty liver disease and obstructive sleep apnea. <i>World Journal of Gastroenterology</i> , 2020 , 26, 2669-2681	5.6	11
22	Prediction of NAFLD occurrence in prediabetes patients. <i>Experimental and Therapeutic Medicine</i> , 2020 , 20, 190	2.1	8
21	Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD. <i>Experimental and Therapeutic Medicine</i> , 2020 , 20, 197	2.1	11
20	Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. <i>Hepatobiliary Surgery and Nutrition</i> , 2015 , 4, 109-16	2.1	68
19	Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2014 , 3, 377-85	2.1	25
18	Primary hepatocellular carcinoma and metabolic syndrome: An update. <i>World Journal of Gastrointestinal Oncology</i> , 2013 , 5, 186-94	3.4	56
17	Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2011 , 3, 219-27	3.4	13
16	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2013 , 5, 470-8	3.4	111
15	Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list. <i>World Journal of Hepatology</i> , 2016 , 8, 376-84	3.4	3

14	Herbal medicines for fatty liver diseases.		
13	Cancer Prevention, Screening, and Early Detection. 2014 , 322-359.e12		1
12	Mouse Models to Study the Effect of Natural Products on Obesity-Associated NAFLD/NASH. <i>Energy Balance and Cancer</i> , 2015 , 247-270	0.2	1
11	Hepatic Fibrosis and Cirrhosis. 2070-2086		
10	Clinical Manifestations of Liver Disease in Diabetes Mellitus. <i>Clinical Gastroenterology</i> , 2018 , 275-315	0	
9	Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver. <i>Journal of International Medical Research</i> , 2020 , 48, 300060520978122	1.4	3
8	Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2021 ,	8	1
7	Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults.. <i>Journal of Healthcare Engineering</i> , 2022 , 2022, 4912961	3.7	0
6	Pancreas and Hepatobiliary Tract. 2022 , 107-126		
5	ACCURACY OF ELASTOGRAPHY IN THE ASSESSMENT OF REDUCTION IN LIVER STEATOSIS AND FIBROSIS IN THE EARLY POSTOPERATIVE PERIOD AFTER BARIATRIC SURGERY. 35,		0
4	Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes.		0
3	NAFLD in Indians: A Myopic Yet Alarming Perspective. 2022 ,		0
2	On the relationship between metabolic capacities and in vivo viscoelastic properties of the liver. 10,		0
1	Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. 2023 , 22,		0